Shorts trapped? CVNA beats expectations

And... AI Trading Bot explained tonight at 7EST                                                                                                                                                                                                                                                                                                                                                                                                                 August 01, 2024 | [Read Online]( And... AI Trading Bot explained tonight at 7EST *together with Brooks Enterprises Please join us TONIGHT — LIVE at 7EST in the [Market Masters Room](for a special guest to give us the lowdown on having eyes on the Market 24/7! ⏰ Set a Reminder and see you there! FOCUS LIST🔎 RDHL - Up over 60% in pre after newly published positive Phase 3 data demonstrates 64% increased efficacy with RedHill's RHB-104 in Crohn's Disease NOVA - Up over 19% in pre after reporting better than expected revenue CVNA - Up over 10% in pre after reporting better than expected earnings and guidance, large short float *together with Brooks Enterprises Exclusive Invite: AI Trading Bot Explained Can an AI trading bot hunt for the best trades 24 hours a day?  Stephen Brooks says YES with his Trade Fusion System AND… He’s joining RagingBull LIVE TONIGHT @7pm EST! [Market Master’s Room Tonight, 7pm ET]( HOTLIST🔥 RDHL - Up over 60% in pre after newly published positive Phase 3 data demonstrates 64% increased efficacy with RedHill's RHB-104 in Crohn's Disease RedHill Biopharma Ltd. (RDHL) is a specialty biopharmaceutical company that primarily focuses on gastrointestinal and infectious diseases. In the pre-market the [company announced]( positive Phase 3 data that demonstrates 64% increased efficacy with RedHill's RHB-104 in Crohn's Disease. Newly published in the peer-reviewed journal Antibiotics, the 331-patient Phase 3 Crohn's disease study data shows the primary endpoint of clinical remission at week 26 was achieved, with high statistical significance, in 36.7% (61/166) of orally administered RHB-104 plus standard of care (SoC) patients, compared to 22.4% (37/165) of placebo plus SoC patients (p=0.0048); Safety profile similar to placebo. Study conducted across more than 100 sites The advanced stage clinical data demonstrating the potential efficacy of oral RHB-104 triple antimicrobial therapy targeting Mycobacterium avium subspecies paratuberculosis (MAP,) supports the paradigm-changing hypothesis of a Mycobacterial basis to Crohn's disease, where high unmet medical need exists. The stock traded up over 60% in the pre-market in reaction to the news. The first target for bulls is the prior resistance level at $0.60 and beyond that the pre-market high at $0.67. Above that, $0.75, $0.80 and $1 come into play. Below $0.60, targets to the downside are $0.50, $0.40 and then a gap fill at $0.3841. NOVA - Up over 19% in pre after reporting better than expected revenue Sunnova Energy International Inc. (NOVA) engages in the provision of energy as a service in the United States. The company offers electricity, as well as offers operations and maintenance, monitoring, repairs and replacements, equipment upgrades, on-site power optimization, and solar energy system and energy storage system diagnostics services. In the after-hours yesterday, the [company reported]( Q2 earnings. Q2 earnings came in at a loss of $0.27 per share vs estimate of a loss of $0.54. This compares to a loss of $0.74 per share a year ago. Revenues for Q2 came in at $219.6 million vs year-ago revenues of $166.38 million. - Unrestricted cash increased by $21.5 million in the second quarter of 2024 - Increased cash generation guidance to $100 million in 2024, $350 million in 2025, and $400 million in 2026 The earnings, revenue beat and positive guidance sent the stock trading up over 19% in the pre-market. The first target for bulls is the pre-market high at $8.65. Above that, targets to the upside are $9, $9.50 and $10. Below $8.65, targets to the downside are $8.30, $8.05, $7.60, $7.40 and then a gap fill at $7.07. CVNA - Up over 10% in pre after reporting better than expected earnings and guidance, large short float Carvana Co. (CVNA) together with its subsidiaries, operates an e-commerce platform for buying and selling used cars in the United States. Its platform allows customers to research and identify a vehicle; inspect it using the company's 360-degree vehicle imaging technology; obtain financing and warranty coverage; purchase the vehicle; and schedule delivery or pick-up from their desktop or mobile devices. The company also operates auction sites In the after-hours yesterday, the [company reported]( earnings (EPS) of $0.14 vs -$0.55 a year ago and forecast annual core profit above Wall Street estimates. It forecast 2024 adjusted EBITDA between $1 billion and $1.2 billion, above analysts' estimates. CVNA has a large short float of over 18% [according to Finviz](. The stock is trading up over 10% in the pre-market in reaction to the earnings and positive guidance. The first target for bulls is the pre-market high at $155.50. Above that, targets to the upside are $160, $180, and $200. Below $155.50, targets to the downside are $150, $147, $146, $140 and then $135. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( *Sponsored content: We’re a proud affiliate for Brooks Enterprises, meaning if you click a link for a product or service, we may earn a commission at no extra cost to you. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](